570 related articles for article (PubMed ID: 21710165)
21. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
22. [The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
Liu Q; Song L; Zhang Y; Wei Y; Xu D; Sun J; Liu X; Xu B; Meng F; Zhou S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):212-5. PubMed ID: 15793790
[TBL] [Abstract][Full Text] [Related]
23. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
[TBL] [Abstract][Full Text] [Related]
24. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
[TBL] [Abstract][Full Text] [Related]
25. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.
Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS
Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336
[TBL] [Abstract][Full Text] [Related]
26. [Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia].
Zhao BR; Tang XW; Cen JN; Jin S; Shi XL; Wei XA; Chang WR; Sun AN; Wu DP
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1375-8. PubMed ID: 21756806
[TBL] [Abstract][Full Text] [Related]
27. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation.
Liu J; Wang Y; Xu LP; Liu DH; Qin YZ; Chang YJ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):929-36. PubMed ID: 24631740
[TBL] [Abstract][Full Text] [Related]
28. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
Chamseddine AN; Willekens C; De Botton S; Bourhis JH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
[TBL] [Abstract][Full Text] [Related]
29. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
30. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
31. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
[TBL] [Abstract][Full Text] [Related]
32. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
33. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
34. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
[TBL] [Abstract][Full Text] [Related]
37. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
[TBL] [Abstract][Full Text] [Related]
39. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]